hepacivirus

Summary

Summary: A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the only member and type species.

Top Publications

  1. ncbi Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
  2. pmc Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
  3. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  4. ncbi Telaprevir for previously untreated chronic hepatitis C virus infection
    Ira M Jacobson
    Weill Cornell Medical College and Center for the Study of Hepatitis C, New York, NY 10021, USA
    N Engl J Med 364:2405-16. 2011
  5. pmc Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
    David L Thomas
    Johns Hopkins University, Division of Infectious Diseases, Baltimore, Maryland 21205, USA
    Nature 461:798-801. 2009
  6. ncbi Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA
    Catherine L Jopling
    Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
    Science 309:1577-81. 2005
  7. pmc Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
    Robert E Lanford
    Department of Virology and Immunology and Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX 78227, USA
    Science 327:198-201. 2010
  8. pmc Boceprevir for previously treated chronic HCV genotype 1 infection
    Bruce R Bacon
    Saint Louis University School of Medicine, St Louis, Mo 63110 0250, USA
    N Engl J Med 364:1207-17. 2011
  9. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
  10. pmc Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011

Detail Information

Publications313 found, 100 shown here

  1. ncbi Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
    ....
  2. pmc Boceprevir for untreated chronic HCV genotype 1 infection
    Fred Poordad
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    N Engl J Med 364:1195-206. 2011
    ..The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies...
  3. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  4. ncbi Telaprevir for previously untreated chronic hepatitis C virus infection
    Ira M Jacobson
    Weill Cornell Medical College and Center for the Study of Hepatitis C, New York, NY 10021, USA
    N Engl J Med 364:2405-16. 2011
    ....
  5. pmc Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
    David L Thomas
    Johns Hopkins University, Division of Infectious Diseases, Baltimore, Maryland 21205, USA
    Nature 461:798-801. 2009
    ..To our knowledge, this is the strongest and most significant genetic effect associated with natural clearance of HCV, and these results implicate a primary role for IL28B in resolution of HCV infection...
  6. ncbi Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA
    Catherine L Jopling
    Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA
    Science 309:1577-81. 2005
    ..Therefore, miR-122 is likely to facilitate replication of the viral RNA, suggesting that miR-122 may present a target for antiviral intervention...
  7. pmc Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
    Robert E Lanford
    Department of Virology and Immunology and Southwest National Primate Research Center, Southwest Foundation for Biomedical Research, San Antonio, TX 78227, USA
    Science 327:198-201. 2010
    ..The prolonged virological response to SPC3649 treatment without HCV rebound holds promise of a new antiviral therapy with a high barrier to resistance...
  8. pmc Boceprevir for previously treated chronic HCV genotype 1 infection
    Bruce R Bacon
    Saint Louis University School of Medicine, St Louis, Mo 63110 0250, USA
    N Engl J Med 364:1207-17. 2011
    ..Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment...
  9. ncbi Telaprevir for retreatment of HCV infection
    Stefan Zeuzem
    Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
    N Engl J Med 364:2417-28. 2011
    ..Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response to therapy with peginterferon alfa plus ribavirin...
  10. pmc Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011
    ..We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations...
  11. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  12. pmc Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
    Takaji Wakita
    Department of Microbiology, Tokyo Metropolitan Institute for Neuroscience, Tokyo 183 8526, Japan
    Nat Med 11:791-6. 2005
    ..The cell culture-generated HCV is infectious for chimpanzee. This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies...
  13. ncbi Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  14. ncbi Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus
    Etienne Meylan
    Department of Biochemistry, University of Lausanne, BIL Biomedical Research Center, Chemin des Boveresses 155, CH 1066 Epalinges, Switzerland
    Nature 437:1167-72. 2005
    ..Cardif thus functions as an adaptor, linking the cytoplasmic dsRNA receptor RIG-I to the initiation of antiviral programmes...
  15. pmc Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor
    Bruno Sainz
    Department of Medicine, University of Illinois Chicago, Chicago, Illinois, USA
    Nat Med 18:281-5. 2012
    ..Thus, we have not only identified NPC1L1 as an HCV cell entry factor but also discovered a new antiviral target and potential therapeutic agent...
  16. ncbi Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
    ..Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment...
  17. ncbi Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
    ..Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment...
  18. ncbi Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
    Peter Simmonds
    Centre for Infectious Diseases, University of Edinburgh, Summerhall, Edinburgh, United Kingdom
    Hepatology 42:962-73. 2005
    ..In conclusion, these proposals provide the framework by which the HCV databases store and provide access to data on HCV, which will internationally coordinate the assignment of new genotypes and subtypes in the future...
  19. ncbi Preliminary study of two antiviral agents for hepatitis C genotype 1
    Anna S Lok
    Department of Internal Medicine, Division of Gastroenterology, 3912 Taubman Center, SPC 5362, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    N Engl J Med 366:216-24. 2012
    ..Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen...
  20. ncbi Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:580-93. 2009
    ..Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared...
  21. ncbi Replication of hepatitis C virus
    Darius Moradpour
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, CH 1011 Lausanne, Switzerland
    Nat Rev Microbiol 5:453-63. 2007
    ..These efforts have already translated into the identification of novel antiviral targets and the development of new therapeutic strategies, some of which are currently undergoing clinical evaluation...
  22. ncbi The lipid droplet is an important organelle for hepatitis C virus production
    Yusuke Miyanari
    Department of Viral Oncology, Institute for Virus Research, Kyoto University, Kyoto 606 8507, Japan
    Nat Cell Biol 9:1089-97. 2007
    ..This study reveals a novel function of LDs in the assembly of infectious HCV and provides a new perspective on how viruses usurp cellular functions...
  23. pmc Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication
    Keril J Blight
    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    J Virol 76:13001-14. 2002
    ....
  24. pmc EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy
    Joachim Lupberger
    Institut National de la Sante et de la Recherche Medicale, U748, Strasbourg, France
    Nat Med 17:589-95. 2011
    ..Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection...
  25. pmc Epidemiology of hepatitis C virus infection
    Miriam J Alter
    University of Texas Medical Branch, Galveston, Texas 77555, USA
    World J Gastroenterol 13:2436-41. 2007
    ..Two 20th century events appear to be responsible for this increase; the widespread availability of injectable therapies and the illicit use of injectable drugs...
  26. pmc miR-122 activates hepatitis C virus translation by a specialized mechanism requiring particular RNA components
    Ashley P E Roberts
    Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK
    Nucleic Acids Res 39:7716-29. 2011
    ..This study provides an important insight into the requirements for the miR-122-HCV interaction, and the broader consequences of miRNAs binding to 5'-UTR sites...
  27. ncbi HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection
    Salim I Khakoo
    Liver Group, Division of Infection, Inflammation, and Repair, Southampton University, Southampton 5016 6YD, UK
    Science 305:872-4. 2004
    ..The data strongly suggest that inhibitory NK cell interactions are important in determining antiviral immunity and that diminished inhibitory responses confer protection against HCV...
  28. pmc Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
    Alexander Ploss
    Center for the Study of Hepatitis C, The Rockefeller University, New York, New York 10065, USA
    Nature 457:882-6. 2009
    ..The identification of OCLN as a new HCV entry factor further highlights the importance of the tight junction complex in the viral entry process, and provides an important advance towards efforts to develop small animal models for HCV...
  29. ncbi Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
    Alexander J Thompson
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Gastroenterology 139:120-9.e18. 2010
    ..We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR...
  30. pmc The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus
    Elisa Scarselli
    Istituto di Ricerche di Biologia Molecolare P Angeletti IRBM, Via Pontina Km 30 600, 00040 Pomezia Rome, Italy
    EMBO J 21:5017-25. 2002
    ..Finally, E2 recognition by SR-BI was competed out in an isolate-specific manner both on the hepatoma cell line and on the human SR-BI-transfected cell line by an anti-HVR1 monoclonal antibody...
  31. ncbi Antiviral strategies in hepatitis C virus infection
    Christoph Sarrazin
    Klinikum der JW Goethe Universität, Medizinische Klinik 1, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Hepatol 56:S88-100. 2012
    ..However, new drugs may be associated with troublesome side effects and drugdrug interactions, and the ideal IFN-free DAA combination remains to be found...
  32. pmc Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex
    Tetsuro Shimakami
    Lineberger Comprehensive Cancer Center and Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7292, USA
    Proc Natl Acad Sci U S A 109:941-6. 2012
    ..miR-122 thus acts in an unconventional fashion to stabilize HCV RNA and slow its decay, expanding the repertoire of mechanisms by which miRNAs modulate gene expression...
  33. ncbi Epidemiology of hepatitis C virus infection in Pakistan
    Nadeem Sajjad Raja
    Department of Medical Microbiology, Southend University Hospital NHS Foundation Trust, Essex, United Kingdom
    J Microbiol Immunol Infect 41:4-8. 2008
    ..Although at present a small proportion of those with chronic HCV infection develop liver failure or hepatocellular carcinoma, it is estimated that the incidence of these advanced disease complications will increase over the coming years...
  34. pmc Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras
    Thomas Pietschmann
    Department of Molecular Virology, University of Heidelberg, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany
    Proc Natl Acad Sci U S A 103:7408-13. 2006
    ..Finally, we describe an E1-specific antiserum capable of neutralizing infectivity of all HCV chimeras...
  35. pmc Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
    Birke Bartosch
    Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, Institut National de la Santé et de la Recherche Médicale U412, IFR 128, Ecole Normale Superieure de Lyon, 69364 Lyon Cedex 07, France
    J Exp Med 197:633-42. 2003
    ..Altogether, these studies indicate that these pseudo-particles may mimic the early infection steps of parental HCV and will be suitable for the development of much needed new antiviral therapies...
  36. pmc A genetically humanized mouse model for hepatitis C virus infection
    Marcus Dorner
    Center for the Study of Hepatitis C, The Rockefeller University, New York, New York 10065, USA
    Nature 474:208-11. 2011
    ....
  37. ncbi Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C
    Masao Honda
    Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Gastroenterology 139:499-509. 2010
    ..Multiple viral and host factors are related to the treatment response to pegylated-interferon and ribavirin combination therapy; however, the clinical relevance and relationship of these factors have not yet been fully evaluated...
  38. ncbi Immunology of hepatitis B virus and hepatitis C virus infection
    Barbara Rehermann
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B16, 10 Center Drive, Bethesda, MD 20892, USA
    Nat Rev Immunol 5:215-29. 2005
    ..This review assesses recent advances in our understanding of viral hepatitis, contrasts mechanisms of virus-host interaction in acute hepatitis B and hepatitis C, and outlines areas for future studies...
  39. ncbi A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
    William Sievert
    Monash Medical Centre and Monash University, Melbourne, Vic, Australia
    Liver Int 31:61-80. 2011
    ..The hepatitis C pandemic has been systematically studied and characterized in North America and Europe, but this important public health problem has not received equivalent attention in other regions...
  40. ncbi Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
    Ann D Kwong
    Vertex Pharmaceuticals, Cambridge, Massachusetts, USA
    Nat Biotechnol 29:993-1003. 2011
    ..Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success...
  41. ncbi The prevalence of hepatitis C virus infection in the United States, 1999 through 2002
    Gregory L Armstrong
    National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Ann Intern Med 144:705-14. 2006
    ..Defining the primary characteristics of persons infected with hepatitis C virus (HCV) enables physicians to more easily identify persons who are most likely to benefit from testing for the disease...
  42. ncbi An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response
    Alessandra Mangia
    Liver Unit, Instituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Gastroenterology 139:821-7, 827.e1. 2010
    ..We evaluated the effects of IL-28B polymorphisms on response to treatment with peginterferon and ribavirin in a well-characterized cohort of genotype 2/3 patients...
  43. ncbi Resistance to direct antiviral agents in patients with hepatitis C virus infection
    Christoph Sarrazin
    J W Goethe University Hospital, Medizinische Klinik 1, Frankfurt am Main, Germany
    Gastroenterology 138:447-62. 2010
    ..We review the parameters that determine resistance, genotypic and phenotypic resistance profiles of DAA agents, and strategies to avoid the selection of resistant variants...
  44. ncbi Assembly of infectious hepatitis C virus particles
    Ralf Bartenschlager
    Department of Infectious Diseases, Molecular Virology, Im Neuenheimer Feld 345, Heidelberg University, D 69120 Heidelberg, Germany
    Trends Microbiol 19:95-103. 2011
    ..Moreover, HCV particle production appears to be strictly linked to very-low-density lipoproteins. In this review, we focus on new insights into the molecular aspects of the architecture and assembly of this unique type of virus particle...
  45. ncbi Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus
    Jean Michel Pawlotsky
    Department of Virology, Hopital Henri Mondor, Université Paris Est Créteil, France
    Hepatology 53:1742-51. 2011
    ....
  46. ncbi Complete replication of hepatitis C virus in cell culture
    Brett D Lindenbach
    Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 309:623-6. 2005
    ..HCVcc replication was inhibited by interferon-alpha and by several HCV-specific antiviral compounds, suggesting that this in vitro system will aid in the search for improved antivirals...
  47. pmc A functional genomic screen identifies cellular cofactors of hepatitis C virus replication
    Andrew W Tai
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Cell Host Microbe 5:298-307. 2009
    ..The host cofactors for HCV replication identified in this study should serve as a useful resource in delineating new targets for anti-HCV therapies...
  48. ncbi Bayesian coalescent inference of past population dynamics from molecular sequences
    A J Drummond
    Department of Zoology, University of Oxford, Oxford, United Kingdom
    Mol Biol Evol 22:1185-92. 2005
    ....
  49. pmc microRNA-122 stimulates translation of hepatitis C virus RNA
    Jura Inga Henke
    Institute of Biochemistry, Faculty of Medicine, Justus Liebig University, Giessen, Germany
    EMBO J 27:3300-10. 2008
    ..miR-122 stimulates HCV translation by enhancing the association of ribosomes with the viral RNA at an early initiation stage. In conclusion, the liver-specific miR-122 may contribute to HCV liver tropism at the level of translation...
  50. ncbi Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs
    Judith M Gottwein
    Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark
    Hepatology 49:364-77. 2009
    ..Finally, neutralizing antibodies in selected chronic phase HCV sera had differential effects against genotype 1-7 viruses...
  51. pmc Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH DHHS, Bethesda, MD 20892, USA
    J Clin Invest 119:1745-54. 2009
    ..This review discusses the clinical, virological, and immunological features of acute and chronic hepatitis C and the role of the immune response in spontaneous and treatment-induced HCV clearance...
  52. pmc Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex
    Denise Egger
    Institute for Medical Microbiology, University of Basel, CH 4003 Basel, Switzerland
    J Virol 76:5974-84. 2002
    ..Virchows Arch. B., 33:233-243, 1980). In view of this finding and the observation that all HCV proteins accumulate on the membranous web, we propose that the membranous web forms the viral replication complex in HCV-infected cells...
  53. pmc Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I
    Rhea Sumpter
    Department of Microbiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9048, USA
    J Virol 79:2689-99. 2005
    ..RIG-I is thus a pathogen receptor that regulates cellular permissiveness to HCV replication and, as an interferon-responsive gene, may play a key role in interferon-based therapies for the treatment of HCV infection...
  54. pmc Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
    Mayla Hsu
    Aaron Diamond AIDS Research Center and Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 100:7271-6. 2003
    ..However, HIV-HCV pseudotype infectivity was inhibited by a recombinant soluble form of CD81 and a mAb specific for CD81, suggesting that CD81 may be a component of a receptor complex...
  55. pmc Robust hepatitis C virus infection in vitro
    Jin Zhong
    Departments of Molecular and Experimental Medicine and Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 102:9294-9. 2005
    ..This system provides a powerful tool for the analysis of host-virus interactions that should facilitate the discovery of antiviral drugs and vaccines for this important human pathogen...
  56. pmc Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
    Thomas Kuntzen
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Hepatology 48:1769-78. 2008
    ..Viral loads were high in the majority of these patients, suggesting that drug-resistant viral strains might achieve replication levels comparable to nonresistant viruses in vivo...
  57. ncbi Hepatitis C virus and host cell lipids: an intimate connection
    Gualtiero Alvisi
    Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany
    RNA Biol 8:258-69. 2011
    ..Thus, HCV exploits lipid metabolism in many ways and may therefore serve as a model system to gain insights into membrane biogenesis, lipid droplet formation and lipid trafficking...
  58. pmc HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response
    Emmanuelle Merquiol
    Liver Unit, Division of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    PLoS ONE 6:e24660. 2011
    ..We wanted to characterize the kinetics of HCV-induced ER stress during infection and assess adaptation mechanisms and their significance...
  59. ncbi Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Hiromitsu Kumada
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 56:78-84. 2012
    ..To evaluate the efficacy and safety of telaprevir in combination with peginterferon-α2b (PEG-IFN) and ribavirin (RBV) in patients with chronic hepatitis C...
  60. pmc Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex
    Erica S Machlin
    Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 108:3193-8. 2011
    ..Finally, this remarkable microRNA-mRNA complex could be targeted with compounds that inactivate miR-122 or interfere with this unique RNA structure...
  61. ncbi Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
    Matthew J Evans
    Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Ave, New York 10021, USA
    Nature 446:801-5. 2007
    ..With CLDN1 we have identified a novel key factor for HCV entry and a new target for antiviral drug development...
  62. pmc Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures
    Svetlana Marukian
    Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, Rockefeller University, New York, NY 10065, USA
    Hepatology 54:1913-23. 2011
    ..The level of IFNλ protein induced was sufficient to inhibit HCVcc infection of naïve cultures...
  63. pmc Hepatitis C virus infection protein network
    B de Chassey
    IMAP Team, Inserm Unit 851, Lyon, France
    Mol Syst Biol 4:230. 2008
    ..CORE protein appeared as a major perturbator of this network. Focal adhesion was identified as a new function affected by HCV, mainly by NS3 and NS5A proteins...
  64. pmc Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers
    Xinxia Peng
    Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA
    BMC Genomics 10:373. 2009
    ..A miRNA-mRNA regulatory module consists of a set of miRNAs and their targets, in which the miRNAs are predicted to coordinately regulate the level of the target mRNA...
  65. ncbi Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
    Tara L Kieffer
    Vertex Pharmaceuticals Inc, Cambridge, MA 02139, USA
    Hepatology 46:631-9. 2007
    ....
  66. ncbi Binding of hepatitis C virus to CD81
    P Pileri
    IRIS, Chiron, Siena 53100, Italy
    Science 282:938-41. 1998
    ..Binding of E2 was mapped to the major extracellular loop of CD81. Recombinant molecules containing this loop bound HCV and antibodies that neutralize HCV infection in vivo inhibited virus binding to CD81 in vitro...
  67. pmc Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment
    Simon Reiss
    The Department of Infectious Diseases, Molecular Virology, Heidelberg University, 69120 Heidelberg, Germany
    Cell Host Microbe 9:32-45. 2011
    ..Our analysis suggests that the direct activation of a lipid kinase by HCV NS5A contributes critically to the integrity of the membranous viral replication complex...
  68. ncbi Hepatitis C virus resistance to protease inhibitors
    Philippe Halfon
    Virological Departement Laboratoire Alphabio, Hopital Ambroise Pare, Marseille, France
    J Hepatol 55:192-206. 2011
    ....
  69. ncbi Course and outcome of hepatitis C
    Jay H Hoofnagle
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Hepatology 36:S21-9. 2002
    The hepatitis C virus (HCV) is a small enveloped RNA virus belonging to the family flaviviridae and genus hepacivirus. The HCV RNA genome is 9,600 nucleotides in length and encodes a single polyprotein that is post-translationally ..
  70. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
    ..We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients...
  71. pmc Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus
    Minkyung Yi
    Center for Hepatitis Research, Institute for Human Infections and Immunity, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555 1019, USA
    J Virol 81:629-38. 2007
    ..We conclude that interactions between NS2 and E1 and p7 as well as between NS2 and NS3 are essential for virus assembly and/or release and that each of these viral proteins plays an important role in this process...
  72. pmc Interferon signaling and treatment outcome in chronic hepatitis C
    Magdalena Sarasin-Filipowicz
    Department of Biomedicine, University of Basel, CH 4031 Basel, Switzerland
    Proc Natl Acad Sci U S A 105:7034-9. 2008
    ....
  73. pmc A genome-wide genetic screen for host factors required for hepatitis C virus propagation
    Qisheng Li
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:16410-5. 2009
    ..The identification of host factors participating in the complete HCV lifecycle will both advance our understanding of HCV pathogenesis and illuminate therapeutic targets...
  74. ncbi Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor
    Birke Bartosch
    Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, INSERM U412, Institut Fédératif de Recherche 128, Ecole Normale Superieure de Lyon, 46 allee d Italie, 69364 Lyon Cedex 07, France
    J Biol Chem 278:41624-30. 2003
    ..Finally, by correlating expression of HCV receptors and infectivity, we suggest that, besides CD81 and SR-B1, additional hepatocyte-specific co-factor(s) are necessary for HCV entry...
  75. ncbi Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    Gastroenterology 132:1767-77. 2007
    ..4A protease inhibitor, has shown strong antiviral activity in phase 1 clinical studies. Because of high levels of HCV replication and the low fidelity of HCV polymerase, selection of resistant isolates during therapy may occur...
  76. ncbi Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
    L E Adinolfi
    Internal Medicine and Hepatology, Second University of Naples, Naples, Italy
    Hepatology 33:1358-64. 2001
    ..05). Our data indicate that steatosis is an important cofactor in increasing liver necroinflammatory activity and in accelerating fibrosis in CHC. Visceral obesity and genotype 3a play a role in the development of steatosis...
  77. pmc Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins
    Hua Huang
    Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390 9046, USA
    Proc Natl Acad Sci U S A 104:5848-53. 2007
    ..These results provide a possible explanation for the restriction of HCV production to the liver and suggest new cellular targets for treatment of HCV infection...
  78. pmc Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission
    Muhammad Idrees
    Division of Molecular Virology and Molecular Diagnostics, National Centre of Excellence in Molecular Biology, University of the Punjab, Lahore 53700, Pakistan
    BMC Infect Dis 8:69. 2008
    ..The specific objective of this study was to find out the frequency of various HCV genotypes present in well-characterized Pakistani HCV isolates and their possible routes of transmission...
  79. pmc Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions
    Eike Steinmann
    Department of Molecular Virology, University of Heidelberg, Heidelberg, Germany
    PLoS Pathog 3:e103. 2007
    ....
  80. pmc Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus
    Christopher T Jones
    Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    J Virol 81:8374-83. 2007
    ..The protease domain of NS2 was required for infectivity, whereas its catalytic active site was dispensable. We conclude that p7 and NS2 function at an early stage of virion morphogenesis, prior to the assembly of infectious virus...
  81. pmc Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome
    Andreas Merz
    Department of Infectious Diseases, Molecular Virology, University of Heidelberg, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany
    J Biol Chem 286:3018-32. 2011
    ..Taken together, we describe a rapid and efficient system for the production of large quantities of affinity-purified HCV allowing a comprehensive analysis of the infectious virion, including the determination of its lipid composition...
  82. ncbi Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics
    Tobias Marcello
    Center for the Study of Hepatitis C, The Rockefeller University, New York, New York 10021, USA
    Gastroenterology 131:1887-98. 2006
    ..We aimed to determine whether IFN-lambda exhibits antiviral activity toward HCV and to compare the signal transduction and effector gene pathways with those of IFN-alpha...
  83. ncbi Mechanism of action of interferon and ribavirin in treatment of hepatitis C
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Building 31, Room 9A27, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 436:967-72. 2005
    ..To optimize current therapeutic strategies and to develop new therapies, a better understanding of the mechanism of action of IFN and ribavirin will be essential...
  84. pmc Characterization of the envelope glycoproteins associated with infectious hepatitis C virus
    Gabrielle Vieyres
    Institut Pasteur de Lille, Center for Infection and Immunity of Lille, F 59019 Lille, France
    J Virol 84:10159-68. 2010
    ..Overall, our study fills a gap in the description of HCV outer morphology and should guide further investigations into virus entry and assembly...
  85. pmc Consensus siRNA for inhibition of HCV genotype-4 replication
    Abdel Rahman N Zekri
    Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, 1st Kasr El Aini st, Cairo, Egypt
    Virol J 6:13. 2009
    ..The current study was conducted to assess whether siRNA can inhibit different HCV genotypes with many quasispecies and to assess whether consensus siRNA have the same effect as regular siRNA...
  86. pmc Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins
    Yinghong Ma
    Department of Microbiology and Immunology, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555 0610, USA
    J Virol 85:86-97. 2011
    ..p7 may play an accessory role by regulating NS2 membrane topology, which is important for NS2-mediated protein interactions and therefore NS2 function...
  87. ncbi Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes
    Marco Antonio Montes-Cano
    Servicio de Inmunologia, Hospital Universitario Virgen del Rocio Instituto de Biomedicina de Sevilla, Sevilla, Spain
    Hepatology 52:33-7. 2010
    ..2 x 10(-5), OR = 0.32; 95%CI, 0.18-0.57); and lastly, patients with sustained response (60.2% versus 32.1% found in patients with nonsustained response, P = 3.1 x 10(-5), OR = 0.31; 95%CI, 0.17-0.56)...
  88. pmc Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity
    Xiao Dong Li
    Howard Hughes Medical Institute, Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9148, USA
    Proc Natl Acad Sci U S A 102:17717-22. 2005
    ....
  89. ncbi Apoptosis in hepatitis C virus infection
    H Bantel
    Institute of Molecular Medicine, University of Dusseldorf, Germany
    Cell Death Differ 10:S48-58. 2003
    ..Nevertheless, apoptosis induction upon HCV infection may critically contribute to liver damage, while inhibition of apoptosis may result in HCV persistence and development of hepatocellular carcinoma...
  90. pmc Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor
    V Agnello
    Lahey Clinic Medical Center, Department of Laboratory Medicine, Burlington, MA 01805, USA
    Proc Natl Acad Sci U S A 96:12766-71. 1999
    ..These findings provide evidence that the family of LDL receptors may serve as viral receptors...
  91. pmc HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro
    Mostafa K El-Awady
    Department of Biomedical Technology, National Research Center, Tahrir Street, PO 12622, Dokki, Cairo, Egypt
    World J Gastroenterol 12:4836-42. 2006
    ..To establish a cell culture system with long-term replication of hepatitis C virus (HCV) genome and expression of viral antigens in vitro...
  92. pmc Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion
    Pablo Gastaminza
    The Scripps Research Institute, Maildrop SBR 10, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 82:2120-9. 2008
    ..These results suggest that by coopting the VLDL assembly, maturation, degradation, and secretory machinery of the cell, HCV acquires its hepatocyte tropism and, by mimicry, its tendency to persist...
  93. pmc Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission
    Claire L Brimacombe
    Hepatitis C Research Group, Institute for Biomedical Research, University of Birmingham, Vincent Drive, Birmingham B15 2TT, United Kingdom
    J Virol 85:596-605. 2011
    ..These observations highlight the importance of targeting host cell receptors, in particular SR-BI, to control viral infection and spread in the liver...
  94. pmc Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms
    Takayuki Hishiki
    Research Institute, Chiba Institute of Technology, Narashino City, Chiba 275 0016, Japan
    J Virol 84:12048-57. 2010
    ..Furthermore, we found that the infectivity of HCV required both the LDLR and scavenger receptor class B, member I (SR-BI), ligands for ApoE. These findings indicate that ApoE is an essential apolipoprotein for HCV infectivity...
  95. pmc Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures
    Martina Buck
    Department of Medicine and Moores Cancer Center, University of California, La Jolla, California, United States of America
    PLoS ONE 3:e2660. 2008
    ..The current Huh-7 systems use cloned, synthetic HCV RNA expressed in hepatocellular carcinoma cells to produce virions, but these cells cannot be infected with naturally occurring HCV obtained from infected patients...
  96. pmc Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly
    Vlastimil Jirasko
    Department of Molecular Virology, University of Heidelberg, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany
    J Biol Chem 283:28546-62. 2008
    ..Finally, we demonstrate that mutations in NS2 blocking HCV assembly can be rescued by trans-complementation...
  97. pmc Lambda interferon inhibits hepatitis B and C virus replication
    Michael D Robek
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
    J Virol 79:3851-4. 2005
    ..These results suggest the possibility that IFN-lambda may be therapeutically useful in the treatment of chronic HBV or HCV infection...
  98. pmc Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies
    Simrat Dhillon
    MRC Virology Unit, Institute of Virology, University of Glasgow, Glasgow, United Kingdom
    J Virol 84:5494-507. 2010
    ..The properties of all of these viruses in terms of receptor reactivity and neutralization by human antibodies were similar to JFH1(N415D), highlighting the importance of the E2 412-423 region in virus entry...
  99. pmc Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation
    Samira Fafi-Kremer
    Institut National de la Sante et de la Recherche Medicale, Unité 748, Strasbourg, France
    J Exp Med 207:2019-31. 2010
    ..These findings provide significant insights into the molecular mechanisms of viral evasion during HCV reinfection and suggest that viral entry is a viable target for prevention of HCV reinfection of the liver graft...
  100. pmc Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture
    Kyung Soo Chang
    Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky College of Medicine, Lexington, Kentucky 40536, USA
    J Virol 81:13783-93. 2007
    ..Our findings also identified apoE as a novel target for discovery and development of antiviral drugs and monoclonal antibodies to suppress HCV virion formation and infection...
  101. pmc Interference of hepatitis C virus RNA replication by short interfering RNAs
    Sharookh B Kapadia
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Proc Natl Acad Sci U S A 100:2014-8. 2003
    ..These results suggest that RNAi may represent a new approach for the treatment of persistent HCV infection...

Research Grants77

  1. Replication Elements in the 5' End of the HCV Genome
    Minkyung Yi; Fiscal Year: 2004
    Hepatitic C virus (HCV) is the single member of the genus hepacivirus in the family Flaviviridae. The genome consists of a single positive-stranded RNA molecule...
  2. MECHANISM OF HEPACIVIRUS REPLICASE ASSEMBLY
    KEVIN RANEY; Fiscal Year: 2003
    ..This work will provide the initial step toward our long term goal of recapitulating HCV replication in vitro using biologically relevant proteins and RNA. ..
  3. Role of nonstructural proteins in pestivirus assembly
    CLAYTON KELLING; Fiscal Year: 2003
    ..We hypothesize that nonstructural proteins play a role in pestivirus and hepacivirus assembly...
  4. Extrahepatic Replication and Viral Evolution of HCV During HCV/HIV Co-infection
    Jason Blackard; Fiscal Year: 2007
    ..This proposal will provide important data on co-factors of virus transmission and identify potential markers of HCV disease progression and treatment failure. [unreadable] [unreadable] [unreadable]..
  5. Interferon-gamma To Treat Chronic HCV Infection
    Andrew Muir; Fiscal Year: 2002
    ..Secondary endpoints include the biochemical response, inflammatory and regulatory cytokine levels, and quality of life during treatment. ..
  6. Mechanisms of Alcohol Mediated Organ and Tissue Damage
    Gyongyi Szabo; Fiscal Year: 2005
    ..3. Increase the involvement of young investigators in the study of alcohol research. 4. Provide an educational forum to participants. ..
  7. Ethanols role in mediation of monocyte suppression
    Gyongyi Szabo; Fiscal Year: 2009
    ..Investigation of the modulation of IL-10 and IL-12 by alcohol in dendritic cell function may identify biomarkers of alcohol-induced immune depression and reveal potential targets for therapy. ..
  8. Hepatitis C Virus, Alcohol and Host Defense
    Gyongyi Szabo; Fiscal Year: 2007
    ..Results from these studies should reveal molecular and cellular mechanisms by which alcohol interacts with HCV infection to accelerate disease persistence and progression. [unreadable] [unreadable]..
  9. T Cell Immunity & Liver Fibrosis in HCV/HIV Coinfection
    Chihiro Morishima; Fiscal Year: 2003
    ..Finally, we will test the hypotheses that HCV/HIV coinfected subjects treated with HAART will demonstrate improved HCV-specific CD4+ T cell function that is not fibrogenic, and is sequestered to the liver. ..
  10. Treatment Disparities/Outcomes of HCV-HIV Co-Infection
    Adeel Butt; Fiscal Year: 2007
    ..The long term objective of the applicant is to make a clinically relevant impact on the HCV treatment patterns and outcomes, especially in the HCV-HIV co-infected patients. [unreadable] [unreadable] [unreadable] [unreadable]..
  11. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2004
    ..Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. ..
  12. CELLULAR IMMUNE RESPONSE IN CHRONIC HEPATITIS C
    David Nelson; Fiscal Year: 2003
    ..These studies will provide insight into basic immunologic principles associated with the host's immune response to this viral infection, as well as provide the basis for new interventional strategies. ..
  13. ROLE OF CYCLOPHILIN A IN THE HIV-1 LIFE CYCLE
    Philippe Gallay; Fiscal Year: 2003
    ....
  14. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth E Sherman; Fiscal Year: 2010
    ....
  15. RECURRENT HEPATITIS B AFTER LIVER TRANSPLANTATION
    Anna Lok; Fiscal Year: 2007
    ..abstract_text> ..
  16. QUALITATIVE NATURE OF ANTIBODIES TO HCV GLYCOPROTEIN SUBUNIT VACCINE IN HUMANS
    Ranjit Ray; Fiscal Year: 2009
    ..Our proposed complimentary experimental approaches in this vaccinated cohort will help in developing successful vaccine strategies for the intervention of the first crucial step of the HCV life cycle. ..
  17. Inhibitors of HIV-Dendritic Cell Interactions as Microbicides
    Philippe Gallay; Fiscal Year: 2008
    ..This approach may not only provide valuable novel microbicides, but it will also allow us to assess the contribution of LC and DC to HIV transmission. ..
  18. Cell mediated Immunity to HCV in HIV+ Persons
    Arthur Kim; Fiscal Year: 2007
    ..This plan will be implemented under the supervision of Dr. Bruce Walker, and will involve bench research, data analysis, and didactic learning. [unreadable] [unreadable]..
  19. Mechanisms of Innate and Adaptive Immunity In HCV
    David Nelson; Fiscal Year: 2009
    ..A better understanding of the immunologic factors that determine resolution or persistence of the infection may help in the design of therapies and vaccines for the control of HCV infection. ..
  20. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    ..abstract_text> ..
  21. Heparan Sulfate Proteoglycans and HIV Pathogenesis
    Philippe Gallay; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  22. Syndecan Agonists and Antagonists as Microbicides
    Philippe Gallay; Fiscal Year: 2007
    ..Thus, microbicides targeting gp120-syndecan interactions will exhibit a broad inhibitory spectrum against sexually transmitted pathogens. [unreadable] [unreadable] [unreadable]..
  23. Microenvironment Modulates HIV Replication in Macrophage
    Philippe Gallay; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  24. Ethanol Effects on Antigen Presentation in Liver Cells
    Natalia Osna; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  25. Functional Activities of HCV Core Protein
    Ranjit Ray; Fiscal Year: 2005
    ....
  26. HCV ENVELOPE GLYCOPROTEINS AND VACCINE DEVELOPMENT
    Ranjit Ray; Fiscal Year: 2003
    ....
  27. Mechanisms and clinical effects of microchimerism in transfused trauma patients
    MICHAEL PAUL BUSCH; Fiscal Year: 2010
    ..TA-MC also offers an opportunity to better understand, and potentially exploit, injury-induced tolerance for future therapeutic purposes. ..
  28. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2007
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. [unreadable] [unreadable] [unreadable]..
  29. HIV-Hepatitis C Virus Interactions and Pathogenesis
    Raymond T Chung; Fiscal Year: 2010
    ..These studies will shed considerable light on HIV-HCV pathogenic interactions and offer a means of productively disrupting these interactions. ..
  30. RCT of Russian IDU Peer Network HIV Prevent Intervention
    Carl Latkin; Fiscal Year: 2007
    ..abstract_text> ..
  31. HEPATIC FIBROSIS: MOLECULAR MECHANISMS
    Mario Chojkier; Fiscal Year: 2009
    ..The regulation of FLIPL activity by MAPK-RSK-C/EBP( signaling in stellate cells. 2. The role of C/EBP( phosphorylation on stellate cell survival. 3. The modulation of stellate cell survival in C/EBP(Glu217 transgenic mice. ..
  32. A Network & Dyad HIV Prevention Intervention for Intravenous Drug User
    Carl Latkin; Fiscal Year: 2007
    ..Main outcome measures will be self-reported sex and injection risk behaviors. Self-reports will be cross-validated by urinalysis of STIs. [unreadable] [unreadable]..
  33. A Long-term Follow-up Study of Drug-Dependent Mothers and Children
    Yih Ing Hser; Fiscal Year: 2010
    ..The study will also lay the foundation for future in-depth investigation of the children of these mothers with histories of substance abuse. ..
  34. Role of Hepatitis B virus X protein in HBV replication.
    Michael J Bouchard; Fiscal Year: 2010
    ..abstract_text> ..
  35. HIV Prevention and Adherence Intervention for HIV Positives and Partners in India
    CARL A contact LATKIN; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: This proposal has high public relevance due to the low rates of HIV medication adherence found in many impoverished communities domestically and internationally. ..
  36. Development of Cellular Assays of Dengue Virus Infection
    Priscilla Yang; Fiscal Year: 2008
    ..These inhibitors can be used to study how dengue virus interacts with its host, and they may also be useful in developing therapies for the treatment of dengue virus infections. [unreadable] [unreadable] [unreadable]..
  37. Reducing HIV/AIDS and Drug Abuse: Linking Compulsory Rehabilitation to Methadone
    Yih Ing Hser; Fiscal Year: 2008
    ..If proven effective, the program can be widely applied in China and in other parts of the world to reduce heroin use and related HIV risk behaviors. [unreadable] [unreadable] [unreadable]..
  38. Alcohol disrupts TLR4 signaling in lipid rafts
    Angela Dolganiuc; Fiscal Year: 2008
    ..Investigation of the early steps of LPS signaling may identify strategies for interfering with the effects of LPS and design therapeutic approaches for improving immunity against infections. [unreadable] [unreadable] [unreadable]..
  39. Novel small-molecule inhibitors of HIV-1 Vif
    GLEN COBURN; Fiscal Year: 2008
    ..Vif-specific inhibitors would have the potential to restore the body's own potent antiviral defense mechanism mediated by APOBEC3G and related proteins. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  40. Incident HIV Infection and Immune Response to Hepatitis C Virus
    Andrea Cox; Fiscal Year: 2007
    ..This, along with excellent mentorship and the supportive and rich environment at JHU, will provide Dr. Cox with the skills she needs to develop into an independent researcher studying HIV/HCV coinfection immunology. ..
  41. INITIATION OF HEPATITIS C VIRUS TRANSLATION
    CHRISTOPHER HELLEN; Fiscal Year: 2001
    ..abstract_text> ..
  42. ORAL ACQUISITION OF HIV INFECTION
    KIMBERLY SHAFER; Fiscal Year: 2003
    ..For this reason, this study addresses a crucial public health goal, one that is long overdue for careful epidemiological study. ..
  43. A 12 YEAR FOLLOW UP OF A COCAINE DEPENDENT SAMPLE
    Yih Ing Hser; Fiscal Year: 2003
    ..abstract_text> ..
  44. DRUG ABUSE: EPIDEMIOLOGY, TREATMENT PROCESS, & OUTCOMES
    Yih Ing Hser; Fiscal Year: 2003
    ..The applicant also expects to grow professionally as Associate Director of the UCLA Drug Abuse Research Center. ..
  45. Developing Murine Models of HCV Replication
    SUSAN UPRICHARD; Fiscal Year: 2004
    ..abstract_text> ..
  46. Trafficking, persistence and evolution of HIV in the CNS
    Peter Simmonds; Fiscal Year: 2005
    ....
  47. Chemical Genetics:Cellular Regulators of HCV (RMI)
    Raymond Chung; Fiscal Year: 2004
    ..Second, discovery of hit compounds that positively or negatively regulate HCV replication will ultimately help lead to identification of novel cellular targets that can be exploited to further interrupt the viral lifecycle. ..
  48. VIRAL HEPATITIS IN CHILDREN OF INJECTION DRUG USERS
    Kathleen Schwarz; Fiscal Year: 2003
    ....
  49. HOMELESS DRUG ABUSE--SERVICE USE, COSTS, CONSEQUENCES
    Carol North; Fiscal Year: 2002
    ..Structural characteristics (organizational, management, and financing) data will be collected from service agencies at baseline to examine their impact on service use. ..
  50. VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES
    Dennis Burton; Fiscal Year: 2004
    ..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..
  51. Project ECHO Extension for Community Healthcare Outcomes
    Sanjeev Arora; Fiscal Year: 2006
    ....
  52. Immunoglobulin Allotypes in Hepatitis C Virus Infection
    JANARDAN PANDEY; Fiscal Year: 2008
    ..Results of this investigation will advance our understanding of the role of host genetic factors in clearance and persistence of hepatitis C virus infection. ..
  53. HCV-ALCOHOL INTERACTIONS-- PATHOGENESIS AND EPIDEMIOLOGY
    Jack Stapleton; Fiscal Year: 2001
    ..These studies may lead to insights on the mechanism of liver injury and help define those patients who are most likely to have progressive liver injury. ..
  54. PATHOGENESIS OF CHRONIC GRAFT VERSUS HOST LIVER DISEASE
    Charles Howell; Fiscal Year: 2001
    ..They will perform these experiments by using knockout mice and neutralization of IL12 and INF gamma by treatment with cytokines. ..
  55. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
    Dennis Burton; Fiscal Year: 2001
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  56. Treatment System Impact & Outcomes of Proposition 36
    Yih Ing Hser; Fiscal Year: 2006
    ..The project will produce recommendations to improve treatment strategies and inform future policy and practice at the national, state, and local levels. ..
  57. MECHANISM OF ACTION OF HIV REGULATORY PROTEINS
    Ajit Kumar; Fiscal Year: 2001
    ....
  58. Mental Health Consequences of Bioterrorism
    Carol North; Fiscal Year: 2002
    ..abstract_text> ..
  59. MEMORY FUNCTION IN ALCOHOLISM--PROCESSES & BRAIN SYSTEM
    Terry Jernigan; Fiscal Year: 2002
    ..These measures will be related to the behavioral indices, using a multiple regression approach, to determine the specific role of each brain region in perceptual. lexical processing, explicit memory and magnitude of priming. ..
  60. Arrays for Protease Activity Profiling
    Igor Kozlov; Fiscal Year: 2008
    ..It will help to identify disorders in cellular regulation that lead to disease, and therefore may result in medical advances in the diagnosis and treatment of disease. ..
  61. VACCINATION AGAINST HERPES SIMPLEX VIRUS
    BARRY ROUSE; Fiscal Year: 2004
    ..Our results should be applicable to the future design of vaccines against HSV and may have application to other situations that require immunomodulation. ..
  62. Capsid assembly inhibitors for the treatment of AIDS
    Atul Agarwal; Fiscal Year: 2006
    ..Phase II of the project will entail further lead optimization and identification of development candidate(s). ..
  63. NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES
    Dennis Burton; Fiscal Year: 2004
    ..To examine the impact of passive immunization in immunoprophylaxis and immunotherapy of a smallpox-like disease in a non-human primate model, we will use an experimental model of monkeypox virus infection ..
  64. Alcohol and Homeless Women's Use of Health Services
    Lillian Gelberg; Fiscal Year: 2004
    ....
  65. Non-parenteral transmission of hepatitis C
    Chia Wang; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  66. Predicting Outcomes of Peginterferon & HCV
    Charles Howell; Fiscal Year: 2006
    ..These studies will provide new insights into the biological basis for the racial disparity in HCV treatment outcomes, and facilitate development of more effective treatments for HCV genotype 1. ..
  67. Pathophysiology of HTLV-I and HTLV-II Infection
    Edward Murphy; Fiscal Year: 2008
    ..Blood will be collected from all subjects, and bronchoalveolar lavage fluid and cerebrospinal fluid from subsets with disease, for studies of HTLV virology and immunology. ..
  68. XI International Conference on Human Retrovirology: HTLV
    Edward Murphy; Fiscal Year: 2007
    ....
  69. DNA Unwinding and Translocation by Helicases
    KEVIN RANEY; Fiscal Year: 2007
    ..Lastly, new methods will be developed to observe helicase translocation and unwinding directly in single molecule experiments. [unreadable] [unreadable]..
  70. HCV NS3: Biological, Biochemical and Structural Analysis
    KEVIN RANEY; Fiscal Year: 2006
    ..We have found that NS5A binds tightly to RNA and to NS5B. We will now examine possible functional interactions between NS5A, NS3, and NS5B and attempt to solve the crystal structure of NS5A. ..
  71. Mechanisms of Cocaine-Induced HIV-1 infection in NHA
    Jessica Reynolds; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  72. REGULATION OF HEPATIC HEME METABOLISM
    HERBERT BONKOVSKY; Fiscal Year: 2009
    ..the molecular mechanisms that mediate heme regulation of ALAS-1 and HO-1 are similar in avian, human, and murine hepatocytes in culture or in intact organisms. ..
  73. PHARMACOTHERAPY FOR XEROSTOMIA IN SJOGREN'S SYNDROME
    SAMUEL HOPKINS; Fiscal Year: 2005
    ..Ultimately, our goal is the full clinical development of 552-02 as a first-line therapy for patients suffering from xerostomia associated with Sjogren's syndrome. ..
  74. Antidepressant & Behavioral Adherence Intervention for Depressed HIV Patients
    Glenn Wagner; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  75. NUCLEOSIDE ANALOGS AS ANTICANCER COMPOUNDS
    Yung Chi Cheng; Fiscal Year: 2007
    ..It should yield novel information for understanding the biochemical determinants of the action of L-OddC, the biochemistry of the enzymes studied and possible novel use of L-OddC for the treatment of solid tumor. ..